Cubist Wins FDA Approval for New Antibiotic Aimed at Skin Infections
The U.S. Food and Drug Administration has approved a new Cubist Pharmaceuticals (NASDAQ: CBST) antibiotic targeting a variety of skin infections, most notably those caused by the so-called MRSA bacteria, which has been named a serious public health threat by the U.S Centers for Disease Control and Prevention, according to a Cubist announcement.
More specifically, the drug, known as Sivextro (tedizolid phosphate), is aimed at the treatment of adult acute bacterial skin and skin structure infections that are caused by susceptible Gram-positive bacteria. That includes MRSA, or methicillin-resistant Staphylococcus aureus.
Taken just once a day over six days, the drug is approved in both intravenous (I.V.) and oral formulations, according to a Cubist announcement. “We are pleased by the FDA approval of Sivextro, which provides a new option for physicians to treat patients with serious bacterial skin infections, including those caused by MRSA,” said Cubist CEO Michael Bonney (pictured above), in a statement. The drug, he said, “provides physicians with flexibility to transition patients from I.V. to oral treatment as required.”
The announcement came after markets closed on Friday.